These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 18045562)

  • 41. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines.
    Robbins JB; Schneerson R; Gotschlich EC; Mohammed I; Nasidi A; Chippaux JP; Bernardino L; Maiga MA
    Bull World Health Organ; 2003; 81(10):745-50; discussion 751-5. PubMed ID: 14758435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Vaccinal strategies in response to new epidemiological challenges in 2010. Reasonable hope for a "B" meningococcal vaccine].
    Nicolas P
    Med Trop (Mars); 2010 Aug; 70(4):325-32. PubMed ID: 22368926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neisseria meningitidis serogroup A vaccines: an overview.
    Vergnano S; Heath P
    Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
    Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
    Sante; 1997; 7(6):384-90. PubMed ID: 9503496
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Which vaccination strategies for African meningococcal meningitis?].
    Saliou P; Debois H
    Bull Soc Pathol Exot; 2002 Dec; 95(5):326-30. PubMed ID: 12696369
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa.
    Robbins JB; Towne DW; Gotschlich EC; Schneerson R
    Lancet; 1997 Sep; 350(9081):880-2. PubMed ID: 9310615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).
    Frasch CE; Preziosi MP; LaForce FM
    Hum Vaccin Immunother; 2012 Jun; 8(6):715-24. PubMed ID: 22495119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
    Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
    Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Control of meningitis outbreaks in the African meningitis belt.
    Obaro SK; Habib AG
    Lancet Infect Dis; 2016 Apr; 16(4):400-2. PubMed ID: 27036337
    [No Abstract]   [Full Text] [Related]  

  • 50. Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics.
    Stephens DS
    Trans Am Clin Climatol Assoc; 2011; 122():115-23. PubMed ID: 21686214
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Epidemiological and control aspects of meningococcal meningitis epidemics in Africa].
    Spiegel A; Moren A; Varaine F; Baudon D; Rey M
    Sante; 1994; 4(3):231-6. PubMed ID: 7921694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.
    Vetter V; Baxter R; Denizer G; Sáfadi MA; Silfverdal SA; Vyse A; Borrow R
    Expert Rev Vaccines; 2016 May; 15(5):641-58. PubMed ID: 26651380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The implications of vaccines for prevention of bacterial meningitis.
    Riordan A
    Curr Opin Neurol; 2010 Jun; 23(3):319-24. PubMed ID: 20173637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Critical review of control strategies for meningococcal meningitis epidemics in Sub-Saharan Africa].
    Chippaux JP; Debois H; Saliou P
    Bull Soc Pathol Exot; 2002 Mar; 95(1):37-44. PubMed ID: 12012963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meningococcal disease in international travel: vaccine strategies.
    Wilder-Smith A
    J Travel Med; 2005 Apr; 12 Suppl 1():S22-9. PubMed ID: 16225803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of respiratory tract infection symptoms and air humidity with meningococcal carriage in Burkina Faso.
    Mueller JE; Yaro S; Madec Y; Somda PK; Idohou RS; Lafourcade BM; Drabo A; Tarnagda Z; Sangaré L; Traoré Y; Fontanet A; Gessner BD
    Trop Med Int Health; 2008 Dec; 13(12):1543-52. PubMed ID: 18983283
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serogroup B meningococcal vaccines.
    Zimmer SM; Stephens DS
    Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 60. W135 invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012.
    Parent du Chatelet I; Barboza P; Taha MK
    Euro Surveill; 2012 May; 17(21):. PubMed ID: 22687826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.